Fig. 6

In vivo anti-tumor efficacy of STAT3/EKEVs in PC9-GR4-AZD1 NSCLC subcutaneous xenografts. A Tumor growth in different treatment groups. Two-way ANOVA. ****P < 0.0001. Error bars represent SEM (n = 7). B Ex vivo photos of tumors. C Tumor weight in different treatment groups. One-way ANOVA. **P < 0.01. ns not significant. Error bars represent SEM (n = 7). D H&E staining images of tumors. E STAT3 Western Blot assays of the protein level and F RT-PCR assays of gene level after STAT3/EKEVs treatment. One-way ANOVA. *P < 0.05, **P < 0.01. ns not significant. Error bars represent SEM (n = 3). G STAT3 expression in tumors was determined by IHC. (scale bar: 100 μm). H Analysis of STAT3 expression in tumor. One-way ANOVA. ***P < 0.001. ns not significant. Error bars represent SEM (n = 3). I Ki67 staining images (scale bar: 100 μm) and J analysis of Ki67 expression in tumors. One-way ANOVA. ****P < 0.0001. ns not significant. Error bars represent SEM (n = 3). K TUNEL staining images (scale bar: 1000 μm). L Body weight in different treatment groups. Two-way ANOVA. ns not significant. Error bars represent SEM (n = 7)